OptiBiotix Health Expands US Operations with New Funding and Subsidiary

OptiBiotix Health ( (GB:OPTI) ) has issued an update.

OptiBiotix Health plc has raised £750,000 through a share placement to fund its expansion in the USA, including leasing a warehousing facility and manufacturing SlimBiome products to meet growing demand. The company has also established a new subsidiary, OptiBiotix Health USA, to strengthen its presence in the American market and reduce tariff risks. The funds will also support sales growth with existing and new partners, particularly in the USA, and increase awareness of its products on e-commerce platforms in India. This strategic move is expected to enhance OptiBiotix’s market positioning and drive profitability.

More about OptiBiotix Health

OptiBiotix Health plc, established in March 2012, operates in the life sciences industry, focusing on developing compounds that modify the human microbiome to prevent and manage diseases and promote wellness. The company is engaged in extensive R&D, collaborating with leading academics to create microbial strains and formulations used in active ingredients and supplements. OptiBiotix partners with over twenty international food and healthcare supplement companies to incorporate its microbiome modulators into various food products and drinks, with a focus on obesity, cardiovascular health, and diabetes.

Average Trading Volume: 269,277

Technical Sentiment Signal: Sell

Current Market Cap: £17.87M

For an in-depth examination of OPTI stock, go to TipRanks’ Stock Analysis page.